|The consensus molecular subtypes of colorectal cancer|
J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ...
Nature medicine 21 (11), 1350-1356, 2015
|Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study|
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The lancet oncology 18 (9), 1182-1191, 2017
|Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy|
S Kopetz, GJ Chang, MJ Overman, C Eng, DJ Sargent, DW Larson, ...
Journal of clinical oncology 27 (22), 3677, 2009
|Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours|
J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ...
The Journal of pathology 232 (2), 199-209, 2014
|Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer|
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
|Cancer classification using the Immunoscore: a worldwide task force|
J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ...
Journal of translational medicine 10 (1), 1-10, 2012
|Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer|
B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu, A Agarwal, DM Maru, ...
Cancer 117 (20), 4623-4632, 2011
|Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases|
DG Blazer III, Y Kishi, DM Maru, S Kopetz, YS Chun, MJ Overman, ...
Journal of Clinical Oncology 26 (33), 5344-5351, 2008
|Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer|
R Dienstmann, L Vermeulen, J Guinney, S Kopetz, S Tejpar, J Tabernero
Nature reviews cancer 17 (2), 79-92, 2017
|CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer|
H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ...
Genome research 23 (9), 1446-1461, 2013
|Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer|
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ...
Journal of clinical oncology 33 (34), 4032, 2015
|Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer|
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
|Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests|
RFA Logan, J Patnick, C Nickerson, L Coleman, MD Rutter, ...
Gut 61 (10), 1439-1446, 2012
|Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …|
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
|Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases|
YS Chun, JN Vauthey, P Boonsirikamchai, DM Maru, S Kopetz, ...
Jama 302 (21), 2338-2344, 2009
|Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for …|
AR Sepulveda, SR Hamilton, CJ Allegra, W Grody, AM Cushman-Vokoun, ...
American journal of clinical pathology 147 (3), 221-260, 2017
|Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600–mutant colorectal cancer|
RB Corcoran, CE Atreya, GS Falchook, EL Kwak, DP Ryan, JC Bendell, ...
Journal of clinical oncology 33 (34), 4023, 2015
|High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome|
A Brouquet, EK Abdalla, S Kopetz, CR Garrett, MJ Overman, C Eng, ...
Journal of clinical oncology 29 (8), 1083, 2011
|Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy|
Y Kishi, S Kopetz, YS Chun, M Palavecino, EK Abdalla, JN Vauthey
Annals of surgical oncology 16 (3), 614-622, 2009
|Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials|
F Meric-Bernstam, L Brusco, K Shaw, C Horombe, S Kopetz, MA Davies, ...
Journal of clinical oncology 33 (25), 2753, 2015